18 Apr 2026

CRC Research Update — April 18, 2026

Creator: The CRC Digest
Published: 2026-04-18T11:49:16Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Immune profiling identifies biomarkers predicting immunotherapy response in dMMR colorectal cancer
Researchers analyzed 39 patients with metastatic dMMR CRC treated with anti-PD-1 therapy using multi-omics profiling to identify tumor and immune biomarkers associated with clinical outcomes, addressing the molecular heterogeneity that contributes to treatment resistance. (Clinical Cancer Research)
Gut microbe Faecalibacterium prausnitzii enhances immunotherapy effectiveness in colorectal cancer
Analysis of patient cohort data shows that abundance of F. prausnitzii in stool samples correlates with improved survival and immunotherapy response, with mouse studies revealing the bacterium reprograms PD-L1 trafficking to sensitize tumors to treatment. (Nature Microbiology)
Phase II trial evaluates cabozantinib in heavily pretreated metastatic colorectal cancer
An open-label, single-arm phase II study assessed the antitumor activity of cabozantinib, a multi-kinase inhibitor targeting angiogenesis, in patients who had progressed after at least two prior lines of therapy. (ESMO Gastrointestinal Oncology)
Phosphorylated protein in blood-derived vesicles shows promise as biomarker for high-risk adenomas and colorectal cancer
Proteomic analysis of plasma-derived small extracellular vesicles identified phosphorylated filamin-A at serine 1459 as a potential biomarker for detecting both high-risk adenomas and colorectal cancer, addressing the need for non-invasive early detection methods. (Scientific Reports)
Study explores how ctDNA testing affects fear of recurrence in colorectal cancer survivors
Researchers examined the psychosocial impact of circulating tumor DNA testing in early-stage colorectal cancer survivors from three randomized trials, focusing on how this emerging prognostic biomarker influences fear of cancer recurrence. (Psycho-Oncology)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Multi-omics platform identifies predictors of immunotherapy response in dMMR colorectal cancer
Despite frequent responses to anti-PD-1 therapy in metastatic dMMR CRC, molecular heterogeneity drives resistance — this study profiled 39 patients to identify candidate biomarkers. (Clinical Cancer Research)
Pediatric Lynch syndrome patient achieves complete response to pembrolizumab
A 12-year-old with Lynch syndrome-associated CRC achieved complete response after switching to off-label pembrolizumab following cardiac toxicity from chemotherapy, adding to limited pediatric data on immunotherapy in MSI-H/dMMR disease. (Drugs in Context)

💙 Living with CRC

Survivorship, quality of life, and supportive care

ctDNA testing and fear of recurrence in colorectal cancer survivors
While ctDNA testing is being established for clinical use, this study from three randomized trials explores how this prognostic biomarker affects survivors' psychological well-being and fear of cancer returning. (Psycho-Oncology)
Non-neutropenic enterocolitis risk identified with CAPOX chemotherapy
A retrospective study examined incidence and risk factors for non-neutropenic enterocolitis requiring hospitalization in patients receiving adjuvant CAPOX, addressing a poorly described complication of this increasingly used regimen. (Clinical Colorectal Cancer)

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

Blood-based biomarker shows promise for detecting high-risk adenomas
Phosphorylated filamin-A in plasma-derived extracellular vesicles emerged as a potential biomarker for both high-risk adenomas and colorectal cancer, offering a non-invasive approach to early detection. (Scientific Reports)
FIT-based screening program demonstrates effectiveness in population study
A population-based program assessed whether identifying FIT-positive individuals for colonoscopy is a more efficient and economical screening approach than universal colonoscopy. (Scientific Reports)

Research continues to advance our understanding of colorectal cancer — from the microbes in our gut to the biomarkers in our blood.

CRC Research Update

Subscribe to The CRC Digest